Correction to: Bone Marrow Transplantation
The original version of the Article stated in the Methods section that Natalizumab was provided by Genentech. In fact, it was provided by Biogen. This has now been corrected in both the PDF and HTML versions of the Article.
Author information
Authors and Affiliations
Corresponding author
Additional information
The original article can be found online at https://doi.org/10.1038/s41409-020-01049-0.
Rights and permissions
About this article
Cite this article
Kekre, N., Kim, H.T., Hofer, J. et al. Correction: Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplant 56, 1217 (2021). https://doi.org/10.1038/s41409-020-01083-y
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41409-020-01083-y
